FDA approval for IPX 203 for treatment of Parkinson’s disease to be launched as Crexont (carbidopa and levodopa) extended-release capsules – Amneal Pharma
Amneal Pharmaceuticals, Inc., announced that the FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). Crexont is a novel, oral formulation… read more.
